Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) had its price objective hoisted by investment analysts at Robert W. Baird from $40.00 to $52.00 in a report issued on Monday,Benzinga reports. The brokerage presently has an "outperform" rating on the stock. Robert W. Baird's target price points to a potential upside of 141.08% from the stock's previous close.
ELVN has been the topic of several other research reports. The Goldman Sachs Group started coverage on shares of Enliven Therapeutics in a research report on Monday. They set a "buy" rating and a $37.00 price objective on the stock. Jones Trading lowered their price objective on shares of Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating on the stock in a research report on Friday, May 16th. Finally, HC Wainwright raised their price objective on shares of Enliven Therapeutics from $39.00 to $40.00 and gave the company a "buy" rating in a research report on Thursday, May 15th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $39.60.
Check Out Our Latest Analysis on Enliven Therapeutics
Enliven Therapeutics Trading Down 1.1%
Shares of Enliven Therapeutics stock traded down $0.23 on Monday, hitting $21.57. 423,893 shares of the company traded hands, compared to its average volume of 292,627. The firm's 50-day simple moving average is $18.65 and its 200 day simple moving average is $20.61. The company has a market cap of $1.06 billion, a P/E ratio of -11.23 and a beta of 0.79. Enliven Therapeutics has a 12-month low of $13.30 and a 12-month high of $30.03.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.06). Analysts predict that Enliven Therapeutics will post -1.95 earnings per share for the current year.
Insider Buying and Selling
In related news, insider Joseph P. Lyssikatos sold 5,000 shares of Enliven Therapeutics stock in a transaction on Monday, April 21st. The shares were sold at an average price of $16.07, for a total value of $80,350.00. Following the transaction, the insider now owns 997,688 shares in the company, valued at $16,032,846.16. This trade represents a 0.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Samuel Kintz sold 12,500 shares of the business's stock in a transaction dated Tuesday, June 17th. The shares were sold at an average price of $22.18, for a total transaction of $277,250.00. Following the completion of the transaction, the chief executive officer now owns 952,892 shares in the company, valued at $21,135,144.56. The trade was a 1.29% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 88,611 shares of company stock worth $1,695,914 in the last 90 days. 25.90% of the stock is owned by company insiders.
Hedge Funds Weigh In On Enliven Therapeutics
Hedge funds have recently modified their holdings of the company. Ameriprise Financial Inc. purchased a new position in shares of Enliven Therapeutics in the fourth quarter valued at about $789,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Enliven Therapeutics by 67.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 43,714 shares of the company's stock valued at $984,000 after acquiring an additional 17,546 shares during the period. Charles Schwab Investment Management Inc. increased its position in shares of Enliven Therapeutics by 2.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 261,888 shares of the company's stock valued at $5,892,000 after acquiring an additional 6,611 shares during the period. Millennium Management LLC increased its position in shares of Enliven Therapeutics by 108.6% in the fourth quarter. Millennium Management LLC now owns 50,804 shares of the company's stock valued at $1,143,000 after acquiring an additional 26,449 shares during the period. Finally, Wellington Management Group LLP increased its position in shares of Enliven Therapeutics by 15.3% in the fourth quarter. Wellington Management Group LLP now owns 80,916 shares of the company's stock valued at $1,821,000 after acquiring an additional 10,746 shares during the period. Hedge funds and other institutional investors own 95.08% of the company's stock.
About Enliven Therapeutics
(
Get Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Further Reading
Before you consider Enliven Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enliven Therapeutics wasn't on the list.
While Enliven Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
